Spero Therapeutics (SPRO) to Release Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO) is expected to be announcing its Q4 2025 results after the market closes on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $26.00 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Spero Therapeutics Price Performance

Shares of NASDAQ:SPRO opened at $2.35 on Tuesday. The company has a market cap of $132.40 million, a P/E ratio of -2.97 and a beta of 1.45. Spero Therapeutics has a 1 year low of $0.51 and a 1 year high of $3.22. The stock’s fifty day moving average price is $2.36 and its 200-day moving average price is $2.30.

Wall Street Analysts Forecast Growth

SPRO has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Spero Therapeutics has a consensus rating of “Reduce”.

Insider Activity

In related news, insider Esther Rajavelu sold 87,917 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the completion of the sale, the insider directly owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SPRO. XTX Topco Ltd bought a new stake in shares of Spero Therapeutics during the 2nd quarter valued at $100,000. Invesco Ltd. bought a new position in Spero Therapeutics in the 2nd quarter worth $43,000. Vanguard Group Inc. lifted its position in Spero Therapeutics by 2.0% during the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock valued at $3,741,000 after purchasing an additional 39,474 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Spero Therapeutics during the third quarter valued at $55,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Spero Therapeutics during the third quarter valued at about $283,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.